Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04157257
- Locations
- 🇨🇳
Southern Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The first hospital of jilin university, Changchun, Jilin, China
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04157699
- Locations
- 🇨🇳
Southern Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The first hospital of Jilin university, Changchun, Jilin, China
Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 440
- Registration Number
- NCT04128163
- Locations
- 🇨🇳
Shanghai sixth people's hospital, Shanghai, Shanghai, China
A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03770624
- Locations
- 🇨🇳
Peking University First Hospital, Peking, Beijing, China
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT03651947
- Locations
- 🇨🇳
The First Affiliated Hospital of Jilin University, Changchun, Jilin, China
A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03557580
- Locations
- 🇨🇳
Qingyuan People's Hospital, Qingyuan, China
A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT03435666
A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients
Phase 1
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer
- Interventions
- Drug: WX-0593 Tablets
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03389815
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03381430
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, China
Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
Phase 1
Completed
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03312283
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath